Limited Offer
Lung Cancer, An Issue of Hematology/Oncology Clinics of North America
- 1st Edition, Volume 37-3 - May 11, 2023
- Editors: Sarah B. Goldberg, Roy S. Herbst
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 8 3 0 6 - 5
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 8 3 0 7 - 2
In this issue of Hematology/Oncology Clinics, guest editors Drs. Sarah B. Goldberg and Roy S. Herbst bring their considerable expertise to the topic of Lung Cancer. Top experts in… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote-
Contains 15 relevant, practice-oriented topics including lung cancer screening; advances in surgical techniques for lung cancer; non-surgical therapy for early-stage lung cancer; locally advanced lung cancer; what’s new in small cell lung cancer; and more.
-
Provides in-depth clinical reviews on lung cancer, offering actionable insights for clinical practice.
-
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Forthcoming Issues
- Preface
- State of the Art of Pathologic and Molecular Testing
- Key points
- Introduction
- Discussion
- Summary
- Clinics care points
- Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer
- Key points
- Introduction
- Liquid biopsy throughout the continuum of care in non-small cell lung cancer
- Liquid biopsy in advanced-stage non-small cell lung cancer: establishing new standards of care at initial diagnosis and at progressive disease in oncogene-driven disease
- Liquid biopsy in treatment response monitoring
- Liquid biopsy in detection of minimal residual disease
- Emerging role of liquid biopsy in screening and early detection
- Summary
- Clinics care points
- Disclosure
- Advances in Surgical Techniques for Lung Cancer
- Key points
- Background
- Current operative techniques
- Surgery in the setting of neoadjuvant therapy
- Segmentectomy and sublobar resection for early-stage non–small cell lung cancer
- Surgical management of ground-glass opacities
- Navigational bronchoscopy
- Summary
- Disclosures
- Funding
- Author contributions
- Nonsurgical Therapy for Early-Stage Lung Cancer
- Key points
- Introduction
- What is stereotactic ablative radiotherapy?
- Clinical history of stereotactic ablative radiotherapy
- Clinical outcomes following stereotactic ablative radiotherapy
- Technical aspects of stereotactic ablative radiotherapy
- High-risk treatment scenarios
- Role of systemic therapy
- Image-guided thermal ablation techniques for early-stage non-small cell lung cancer
- Ablation for early-stage non-small cell lung cancer
- Summary
- Clinics care points
- Source of funding
- Declaration of interest
- Supplementary data
- The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer
- Key points
- Introduction
- Adjuvant systemic therapy in non-small cell lung cancer
- Neoadjuvant systemic therapy in non-small cell lung cancer
- Preoperative/perioperative versus postoperative systemic therapy
- Additional considerations and future directions
- Clinics care points
- Locally Advanced Lung Cancer
- Key points
- Introduction
- Sequential versus Concurrent Chemoradiation Therapy
- Role of immunotherapy
- Personalized, genotype-directed therapy
- Summary
- Clinics care points
- Disclosure
- First-Line Treatment of Driver-Negative Non–Small Cell Lung Cancer
- Key points
- Introduction
- PD-L1 greater than or equal to fifty percent
- PD-L1 less than fifty percent
- Never-smokers
- Duration of immunotherapy
- Immunotherapy sensitivity, resistance, and exploratory biomarkers
- Summary
- Clinics care points
- Disclosures
- Targeted Therapy for Non–Small Cell Lung Cancer: First Line and Beyond
- Key points
- Introduction
- Prevalence and identification of actionable oncogenic drivers
- The fusion drivers: ALK, ROS1, RET, and NTRK
- EGFR activating mutations
- HER2 activating mutations
- BRAF mutations
- MET exon 14 skipping mutations
- KRAS G12C mutations
- Emerging oncogenic drivers as therapeutic targets
- Immunotherapy in oncogene-driven lung cancer
- Perioperative use of targeted therapy
- Discussion
- Clinics care points
- Disclosure
- What Is New in Small Cell Lung Cancer
- Key points
- Introduction
- Summary
- Clinics care points
- Lung Cancer Supportive Care and Symptom Management
- Key points
- Introduction
- Background
- Mortality
- Morbidity
- Prognostic uncertainty
- Oncologic emergencies
- Symptoms
- Palliative care
- Lung cancer survivorship
- Summary
- Disclosure
- New Therapies on the Horizon
- Key points
- Introduction
- Strategies to overcome immune checkpoint inhibitors resistance
- Antibody-drug conjugates
- Discussion of future directions
- Summary
- Clinics care points
- Disclosure of funding
- Conflicts of interest
- No. of pages: 240
- Language: English
- Edition: 1
- Volume: 37-3
- Published: May 11, 2023
- Imprint: Elsevier
- Hardback ISBN: 9780443183065
- eBook ISBN: 9780443183072
SG
Sarah B. Goldberg
RH